These are among the best-selling joint supplements, but the highest-quality independent trial found the popular combination no better than a placebo for knee pain, and leading osteoarthritis guidelines don't recommend them. They're very safe, and a subset of people report relief, so a defined trial isn't unreasonable — just don't expect much.
The one-paragraph version
Glucosamine and chondroitin are building blocks of cartilage, and the theory is that supplementing supports the joint S1. The evidence doesn't cooperate: the large, independent GAIT trial found neither alone nor combined beat placebo for reducing knee pain overall, and a major network meta-analysis concluded the effect on pain is clinically irrelevant S1S2. Some other analyses show small benefits, and prescription-grade glucosamine sulfate has better data than the US OTC form, so the picture is mixed rather than zero S3. They're safe and cheap-ish; a time-limited trial is the honest framing, not a confident recommendation.
What it is and how it works
Glucosamine and chondroitin sulfate are naturally occurring components of cartilage and connective tissue; supplements are usually derived from shellfish shells (glucosamine) or animal cartilage (chondroitin) S1. The rationale is that supplying these substrates might support cartilage maintenance or reduce the inflammation of osteoarthritis — a plausible mechanism that has largely not translated into reliable clinical benefit S1S2.
What the evidence actually supports
Knee pain (the headline claim) — largely negative. The NIH-funded GAIT trial (1,583 patients) found that glucosamine hydrochloride, chondroitin sulfate, and their combination were not significantly better than placebo at reducing knee osteoarthritis pain overall S1. A large network meta-analysis similarly concluded that any effect on joint pain was too small to be clinically meaningful S2.
Mixed and formulation-dependent signals. Some meta-analyses report small improvements in pain or function, and prescription-grade crystalline glucosamine sulfate (used in parts of Europe) has more favorable data than the glucosamine hydrochloride common in US supplements — so the form may matter S3.
Guideline position — not recommended. Major osteoarthritis guidelines (e.g., OARSI) do not recommend glucosamine/chondroitin for symptom relief, reflecting the weak overall evidence S2.
Who actually benefits
Possibly a subgroup with moderate knee osteoarthritis pain — a GAIT secondary analysis hinted at benefit there, though it wasn't robust S1. Realistically, anyone trying it should treat it as an individual experiment: give it a defined window, and stop if it isn't clearly helping S1S2.
Dosing (standard, well-established)
Trials typically use 1,500 mg/day of glucosamine and 1,200 mg/day of chondroitin sulfate, often split across the day, assessed over several weeks to months S1. Because benefits (if any) are slow and modest, a reasonable approach is a defined trial of a couple of months, then an honest reassessment S1S3.
Safety
Glucosamine and chondroitin are well tolerated, with mild GI upset the most common complaint; serious adverse effects are uncommon S1. Practical cautions: many glucosamine products are shellfish-derived (a consideration for shellfish allergy), chondroitin has mild blood-thinning potential so people on anticoagulants should check first, and there are theoretical effects on blood sugar worth noting for people with diabetes S1. As with all supplements, product content varies, so third-party testing is worth looking for.
The marketing myths
- "Clinically proven to rebuild cartilage." The best independent trial found no meaningful pain benefit, and guidelines don't recommend it S1S2.
- "The combination works better." GAIT found the combination no better than placebo overall S1.
- "All glucosamine is the same." The sulfate (prescription-grade) and hydrochloride forms have different evidence bases S3.
- "If it's sold everywhere it must work." Popularity here outruns the evidence S2.
Sources
Every reference below is a primary source cited in this guide.